argenx (ARGX) vs BioNTech (BNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
argenx (ARGX) has outperformed BioNTech (BNTX) over the past year, gaining 16.4% versus a loss of 10.2%. Over five years, ARGX leads with a +216.1% price change compared with -61.5% for BNTX. argenx is the larger company by market cap ($57.74 billion vs $23.93 billion), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | BNTX |
|---|---|---|
| Share price | $928.44 | $95.25 |
| Market cap | $57.74B | $23.93B |
| 1-day change | -0.22% | -0.50% |
| YTD return | +10.40% | +0.05% |
| 1-year return | +16.44% | -10.19% |
| 5-year return | +216.08% | -61.54% |
| P/E ratio (TTM) | 35.38 | — |
| Forward P/E | 26.74 | — |
| EPS (TTM) | $26.24 | $-7.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.29B | — |
| 52-week high | $1,072.75 | $124.00 |
| 52-week low | $661.85 | $79.52 |
| Distance from 52-week high | -13.45% | -23.19% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +27.12% | +21.56% |
| Average volume | 283.80K | 1.16M |
| Shares outstanding | 62.19M | 251.20M |
| Employees | 1,863 | 7,807 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 2.4 times larger than BioNTech by market value ($57.74B vs $23.93B).
- ARGX has outperformed BNTX by 26.6 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
ARGX vs BNTX FAQ
Which is bigger, argenx or BioNTech?
argenx (ARGX) is larger, with a market capitalization of $57.74B compared with $23.93B for BioNTech (BNTX).
Which stock has performed better over the past year, ARGX or BNTX?
ARGX returned +16.44% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and BioNTech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.